Education
About Us
Working with TipRanks
Follow Us
Zai Lab (ZLAB)
NASDAQ:ZLAB
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.38Last Year’s EPS
-0.82Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 16.33%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with strong revenue growth and promising pipeline developments. While there were some temporary challenges such as seasonal declines and inventory dynamics affecting VYVGART sales, the company remains optimistic about achieving its full-year targets.Company Guidance
During Zai Lab's first quarter 2025 earnings call, the company reaffirmed its full-year revenue guidance of $560 million to $590 million, anticipating accelerating sales growth that would help achieve profitability by Q4 2025. The company highlighted its differentiated portfolio and strong business fundamentals, targeting $2 billion in revenue by 2028. Zai Lab's lead global asset, ZL-1310, is progressing with updated Phase I data expected at ASCO in June, aiming for potential FDA approval in 2027. The company reported a total revenue increase of 22% year-over-year to $106.5 million, with operating loss improved by 20% to $56.3 million. The adjusted operating loss, excluding non-cash items, improved by 25% to $37.1 million. Zai Lab ended the quarter with a cash position of $857.3 million and reiterated its focus on achieving quarter-over-quarter growth through the remainder of the year.Strong Revenue Growth
Total revenue grew 22% year-over-year to $106.5 million in the first quarter, driven by increased sales for VYVGART, ZEJULA, and NUZYRA.
Improved Operating Loss
Operating loss improved by 20% to $56.3 million and by 25% to $37.1 million on an adjusted basis.
Promising Pipeline Developments
ZL-1310 is on track for a potential FDA approval in 2027. ZL-6201 and ZL-1503 are expected to enter clinical trials this year.
Positive VYVGART Outlook
VYVGART sales are expected to outpace total revenue growth, driven by increased patient demand and expanded access.
Strong Financial Position
The company ended the quarter with a cash position of $857.3 million.
---
ZLAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ZLAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $28.36 | $29.14 | +2.75% |
Feb 27, 2025 | $35.07 | $34.38 | -1.97% |
Nov 12, 2024 | $31.09 | $28.96 | -6.85% |
Aug 06, 2024 | $18.11 | $16.65 | -8.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Zai Lab (ZLAB) report earnings?
Zai Lab (ZLAB) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Zai Lab (ZLAB) earnings time?
Zai Lab (ZLAB) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZLAB EPS forecast?
ZLAB EPS forecast for the fiscal quarter 2025 (Q2) is -0.38.
---